JAK2 V617F/C618R mutation in a patient with polycythemia vera:A case study and review of the literature
Authors:
- Tae Sung ParkTPTae Sung Park
- Ho-Young MaengHMHo-Young Maeng
- Young-Kyu SunYSYoung-Kyu Sun
- Young-Ah KimYKYoung-Ah Kim
- Jeong-Hae KieJKJeong-Hae Kie
- Eun Hae ChoECEun Hae Cho
- Jaewoo SongJSJaewoo Song
- Kyung-A. LeeKLKyung-A. Lee
- Borum SuhBSBorum Suh
- Jong Rak ChoiJCJong Rak Choi
- 1 February 2009
- journal article
- case report
- Published by Elsevier in Cancer Genetics and Cytogenetics
- Vol. 189 (1) , 43-47
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- JAK2 Mutations are present in all cases of polycythemia veraLeukemia, 2007
- Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithmsLeukemia, 2007
- Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemiaBlood, 2006
- JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosisBlood, 2006
- Detection of the Activating JAK2 V617F Mutation in Paraffin-Embedded Trephine Bone Marrow Biopsies of Patients with Chronic Myeloproliferative DiseasesThe Journal of Molecular Diagnostics, 2006
- Mutational screen reveals a novel JAK2 mutation, L611S, in a child with acute lymphoblastic leukemiaLeukemia, 2005
- The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemiaBlood, 2005
- JAKing up hematopoietic proliferationCancer Cell, 2005
- A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia veraNature, 2005
- Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disordersThe Lancet, 2005